Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Thursday, May 14, 2026

Snapshot: May 14, 2026 · 6:00 PM 100 stocks analyzed

Up Day

Thu, May 14, 2026 Broad Rally Extreme

Broad rally with extreme dispersion as micro-caps and tech surged while earnings misses and restructurings hammered healthcare and select names.

60% S&P 500 climbed 0.78%, NASDAQ +0.88%, and Russell 2000 +0.67% in a classic broad-rally regime, with VIX falling 3.4% as risk appetite expanded across all cap sizes and sectors.
25% Extreme dispersion dominated the tape: 50 gainers averaged +51.5% (max CREG +257%), while 50 losers averaged -25.2% (TDIC -97%), signaling a stock-pickers' day where single-stock catalysts and earnings beats/misses drove wild swings independent of macro direction.
15% Technology led gainers with 31% concentration (LESL +145%, QUCY +124%, AIIO +116% on news-grounded catalysts), while Healthcare dominated losers (27% of decliners) and reverse-split announcements (YYAI -39%, ADTX -21%, PPCB -21%) signaled financial distress offsetting the bullish overall tape.

Technology drove 31% of gainers 5 names returned after long absences DXF · 3-day gainers streak AEHL · 3-day gainers streak LESL — first appearance SNAL — first appearance

Market Regime

Thu, May 14, 2026 Risk-On conf: high macro · prototype

+34

Tailwind −100 … +100 · + tailwind / − headwind

VIX17.3 p51 Drawdown0.0% Held24d · extended SinceApr 13

Top drivers: S&P vs 20d avg ▲ S&P vs 50d avg ▲ S&P 20d return ▲

processId: history-market-regime

Market Indexes

Thu, May 14, 2026 4

S&P 500

7,502.04

+57.79

+0.78%

NASDAQ Composite

26,635.22

+232.88

+0.88%

Russell 2000

2,863.09

+19.15

+0.67%

VIX

17.26

−0.61

-3.41%

Biggest Gainers

Thu, May 14, 2026 50

CREG

Smart Powerr Corp.Utilities

$0.71+$0.51

+257.2%

NASDAQ · Mkt cap $499 K

No news headlines were found in the last 48 hours, so the driver of this 257% gain remains unknown based on available information, though micro-cap stocks often experience large moves on volume spikes or unverified rumors.

Smart Powerr Corp. is a micro-cap stock trading at $0.71 with a massive single-day gain of 257%, yet no news has been identified in the last 48 hours on Yahoo Finance. This is a critical disconnect. Stocks at this price point and market cap typically move sharply on thin volume, making them susceptible to several possible catalysts that may not yet have propagated to major news feeds: unconfirmed press releases posted directly to company channels, social media promotion or retail investor coordination, short covering or technical breakouts on low liquidity, or delayed coverage of older announcements. Without corroborating headlines or knowledge of the company's specific structure or recent filings, attribution is speculative. The absence of news within the standard 48-hour window is itself notable and suggests either an extremely recent development not yet widely covered, a micro-cap-specific announcement not indexed by major financial news aggregators, or potentially a technical/momentum event unrelated to fundamental news.

LESL

Leslie's, Inc.Consumer Cyclical

$3.50+$2.07

+144.8%

NASDAQ · Mkt cap $6.1 M

Leslie's beat Q2 revenue expectations by 14% and reported 4.3% sales growth with 8% customer count growth, driving a 26% after-hours surge that continued into a 145% intraday gain the following day.

Leslie's reported second-quarter results on May 13 that exceeded analyst estimates. The company delivered revenue growth of 4.3% year-over-year to $184.7 million, beating consensus by approximately 14%. The earnings call also highlighted an 8% customer count growth and a 6.6% comparable sales increase. The stock surged 26% in after-hours trading immediately following the earnings release, climbing from roughly $1.41 to $1.80. The continued momentum into May 14, reaching $3.50 and ranking as the second-largest gainer that day, suggests sustained investor enthusiasm. One headline noted afternoon weakness driven by gas price concerns and discretionary spending fears, yet the stock still closed substantially higher, indicating the earnings beat overwhelmed broader market headwinds. The company reiterated full-year guidance, providing additional confidence to the market.

DXF

Eason Technology LimitedFinancial Services

$1.75+$0.99

+130.2%

AMEX · Mkt cap $1.6 M

DXF surged 130% on Thursday as Asian ADRs broadly rallied, but the single headline provided does not explain the stock's specific outsized move or identify any company-specific catalyst.

The only news item supplied is a generic statement that Asian equities traded as American Depositary Receipts were higher Thursday morning. This confirms a sector-wide tailwind but does not account for DXF's exceptional +130% outperformance versus the broader ADR move. The headline is incomplete and does not establish why DXF specifically jumped so sharply. Possible drivers consistent with this volatility profile include short-covering (Eason Technology is a small-cap that may have a concentrated short position), a delayed earnings announcement or guidance revision not yet captured in the RSS feed, a material contract win, or sustained retail interest in the name following prior momentum. Without company-specific news, the precise cause remains speculative.

QUCY

Mainz Biomed N.V.Healthcare

$3.00+$1.66

+123.9%

NASDAQ · Mkt cap $15 M

Quantum Cyber announced an exclusive autonomous drone platform deal and secured a high-profile board addition (former VA Secretary Peter O'Rourke), capitalizing on a Trump administration push for $55 billion in drone warfare spending, likely driving the 124% surge.

On May 13-14, Quantum Cyber executed two material announcements: (1) an IP license agreement with BP United Inc. for an exclusive autonomous drone platform, timed explicitly to the Trump administration's $55 billion drone warfare budget initiative, and (2) the appointment of Peter O'Rourke Sr., former Acting Secretary of the Department of Veterans Affairs and current Nasdaq Board Chairman, to its board of directors. O'Rourke brings credibility in defense, government contracting, and capital markets. The pairing of a concrete defense-tech contract with a politically-connected board member in a macro environment of elevated defense spending appears to have triggered significant institutional and retail buying. The stock's rank as the fourth-biggest gainer suggests broad market participation rather than isolated speculation.

YMAT

J-Star Holding Co., Ltd. Ordinary SharesBasic Materials

$1.87+$1.02

+118.9%

NASDAQ · Mkt cap $7.3 M

No relevant news headlines were provided for YMAT. The 118.87% surge is likely driven by technical factors such as low float, short squeeze dynamics, or delayed reaction to an unmentioned catalyst, as J-Star is a micro-cap stock prone to volatile moves.

The news snippet provided mentions only other gainers (AIIO, FCHL) in a general market mover roundup from May 13, but contains no specific information about YMAT itself. J-Star Holding is a micro-cap NASDAQ stock with a market cap in the tens of millions range based on the price action. Stocks in this category frequently experience outsized percentage moves driven by low liquidity, short squeezes, retail trading interest, or technical breakouts rather than fundamental news. The lack of a substantive headline tied to YMAT makes it impossible to confirm whether the move reflects new company-specific information, a delayed market reaction to prior news not captured in the RSS feed, or purely technical/momentum-driven activity common to illiquid small-cap names.

AIIO

Robo.ai Inc.Consumer Cyclical

$5.64+$3.03

+116.1%

NASDAQ · Mkt cap $487 M

Robo.ai announced the launch of NeuroStream™, a new AI video compression and edge computing platform through subsidiary Neurovia AI, alongside a CTO appointment, triggering a 116% gain as investors responded to the technology rollout and physical AI infrastructure positioning.

The stock rose 116% on May 14 following back-to-back announcements about Neurovia AI's NeuroStream™ platform launch and the appointment of Mansoor Ali Khan as CTO. The company had already gained 65% on May 13 after the CTO announcement, suggesting the market was building anticipation. The May 14 headlines framed NeuroStream as a core offering targeting AI-native compression and edge computing—areas with high investor interest in the "physical AI" theme. The timing of the technology platform launch paired with leadership appointments appears to have catalyzed the dramatic move. Notably, the stock trades on light volume with a $25 million market cap, making it susceptible to outsized percentage moves on positive announcements. The news itself is real but lacks specifics on revenue, partnerships, or adoption metrics that would typically validate such a large revaluation.

SNAL

Snail, Inc. Class A Common StockCommunication Services

$1.08+$0.58

+115.1%

NASDAQ · Mkt cap $26 M

Snail Inc reported strong Q1 2026 earnings that beat analyst estimates and returned the company to profitability, while also unveiling an ambitious pipeline of three AAA titles in final development stages and expanding into Latin America, driving the stock up 115%.

The headlines establish that Snail Inc released Q1 2026 results on May 14 that exceeded expectations on both revenue and profitability metrics, with reported revenue growth of 35.7%. The company also announced it has three AAA titles in final development phases, which management characterized as a significant competitive positioning move. Additionally, multiple headlines highlight expanded Latin America gaming partnerships and market presence as a strategic growth initiative. The after-hours move of 82% on May 13 and the continued 115% intraday gain on May 14 directly correlate with the earnings release and forward guidance around the content pipeline. These are concrete operational and financial developments that typically drive substantial moves in gaming stocks, particularly when profitability returns and major product launches are imminent.

FSHPR

Flag Ship Acquisition Corporation

$0.15+$0.07

+85.0%

NASDAQ

No news headlines were found in the last 48 hours for FSHPR, so the 85% jump cannot be attributed to a specific announced event; the move likely reflects either technical trading activity or unconfirmed market-moving information not yet captured in public headlines.

The absence of any recent news headlines presents a challenge in explaining the 85% intraday gain. FSHPR is a blank-check acquisition company (SPAC), a security class that historically exhibits high volatility and can move sharply on rumors of pending merger announcements, insider activity, or changes in the company's timeline to find a target. SPACs are also susceptible to retail-driven momentum trading and technical rebounds after extended periods of decline. Without visible headline confirmation, the move could stem from an unannounced or delayed-to-appear press release, a social media catalyst, insider buying, or simply short covering and technical momentum in a low-priced security. The 8 ranking suggests genuine broad-market interest, but the lack of corroborating news limits confidence in pinpointing the specific trigger.

MOBX

Mobix Labs, Inc.Technology

$3.11+$1.37

+78.7%

NASDAQ · Mkt cap $18 M

Mobix Labs announced a rare earth and critical minerals acquisition targeting the defense and national security sector, along with an amendment to senior secured convertible notes with a new investor, driving the 78.74% surge.

Three related announcements on May 14 explain the move. The headline news is Mobix's acquisition of a U.S. rare earth and critical minerals company serving defense and national security markets, a strategically valuable sector given current geopolitical priorities and supply chain concerns. Concurrently, the company amended its senior secured convertible note and entered an investor rights agreement with Leviston Resources, suggesting fresh capital support or improved financial footing. For a smaller-cap stock like MOBX, an accretive defense-adjacent acquisition combined with debt restructuring and new institutional backing typically triggers substantial relief buying. The market rewarded both the strategic move into a high-margin sector and the refinancing clarity in a single day, consistent with how microcaps respond to transformational announcements.

YOOV

Concorde International Group Ltd.Industrials

$1.22+$0.53

+76.2%

NASDAQ · Mkt cap $139 M

Concorde International announced multi-year security contracts worth over $10 million in Singapore on May 14, which likely drove the 76% gain as the deal strengthens revenue visibility and positions the company in AI-enabled security services.

The company issued press releases on May 14 announcing the award of multi-year contracts exceeding $10 million for integrated security solutions in Singapore. This is a concrete revenue visibility event for a small-cap security technology provider. The contracts are explicitly described as multi-year, meaning recurring revenue, and tied to AI-enabled security deployments, which aligns with current investor interest in applied AI solutions. For a company trading at $1.22 with relatively low liquidity typical of micro-cap NASDAQ stocks, a $10 million multi-year contract can represent meaningful growth or a significant portion of annual revenue, justifying a material single-day jump. The timing of the announcement matching the trading date strongly suggests investor response to the news itself rather than a delayed catalyst or technical factor.

CBRS

Cerebras Systems Inc.Technology

$311.07+$126.07

+68.1%

NASDAQ · Mkt cap $44 B

No news headlines appeared in the last 48 hours, so the 68% jump likely reflects either a delayed market reaction to an earlier announcement, technical trading activity, or untracked news affecting the semiconductor AI chip maker.

Cerebras Systems experienced a massive single-day surge with no corresponding headline coverage in the 48-hour window provided. This gap between move and news suggests either the catalyst occurred outside the tracked period, the market is reacting to broader AI chip sector momentum, or the catalyst has not yet been formally announced or widely reported. Cerebras develops specialized AI processors, a sector sensitive to major contract wins, product announcements, or shifts in AI infrastructure demand. A jump of this magnitude in a hardware systems company typically correlates with major business developments such as enterprise deals, revenue guidance raises, or positive third-party validation of product performance. Without specific news, it is impossible to confirm the precise trigger, though the company's position in the competitive AI acceleration market makes it responsive to industry trends and customer announcements that may circulate before formal press releases.

IPHA

Innate Pharma S.A.Healthcare

$2.17+$0.85

+64.4%

NASDAQ · Mkt cap $205 M

Innate Pharma reported Q1 2026 business results and clinical updates on its three priority assets on May 13, likely triggering the 64% rally as investors reacted positively to the clinical pipeline progress disclosed in the earnings call and press release.

The company released Q1 2026 financial results and a business update on May 13 centered on three clinical programs: lacutamab in cutaneous T-cell lymphoma, IPH4502 (a Nectin-4 antibody-drug conjugate) in advanced solid tumors, and a third asset referenced but not fully detailed in the headlines provided. The earnings call highlights and formal business update were published within hours of each other on May 13, creating a natural catalyst window for the May 14 gain. Without access to the full text of the earnings release or call, I cannot confirm whether specific clinical trial results, regulatory milestones, or financial metrics beat consensus expectations. However, the 64% single-day jump suggests investors viewed the disclosed clinical or operational data as materially positive for the pipeline outlook. Biotech stocks with early-stage clinical assets are highly sensitive to development-stage announcements.

ZSPC

zSpace, Inc.Technology

$0.24+$0.09

+60.0%

NASDAQ · Mkt cap $960 K

zSpace announced Q1 2026 results and launched a strategic alternatives review on May 14, which likely triggered the 60% jump as the board's exploration of alternatives signals potential value unlock or acquisition interest.

The headline from May 14 indicates zSpace reported first quarter 2026 financial results and that its board of directors launched a strategic alternatives review to unlock shareholder value. The timing is precise—the announcement came on the same day as the stock's massive 60% gain, establishing a clear temporal link. A strategic alternatives review typically encompasses options ranging from asset sales to merger and acquisition activity, and such announcements often catalyze sharp moves in illiquid or distressed equities trading on OTC markets. The second headline about Sangoma Technologies appears unrelated to zSpace and likely appeared in the RSS feed coincidentally. Without access to the specific financial results or details of the alternatives review, we cannot determine whether the move was driven by better-than-expected earnings, guidance changes, or simply the signaling effect of the board's willingness to explore alternatives.

AMPGR

Amplitech Group, Inc. Series A Right

$0.06+$0.02

+58.0%

NASDAQ

AmpliTech reported strong Q1 2026 revenue growth and significant gross margin expansion on May 13-14, which likely drove the 58% gain in the Series A Right security as investor confidence in the company's outlook improved.

The news headlines establish that AmpliTech (AMPG) released Q1 2026 earnings results on May 13-14 showing sharply higher revenue and wider gross margins year-over-year. Management reaffirmed confidence in full-year revenue guidance despite acknowledging some potential timing risks. This positive earnings surprise and margin expansion, combined with maintained forward guidance, typically triggers buying interest in a micro-cap stock. The AMPGR ticker represents a Series A Right, a type of security that derives value from the underlying common stock and may amplify price movements. The 58% single-day jump aligns with a positive earnings catalyst in a thinly-traded security class where percentage moves can be outsized relative to the base stock.

RIBBR

Ribbon Acquisition Corp Rights

$0.33+$0.10

+43.5%

NASDAQ · Mkt cap $1.2 M

No news headlines were found in the last 48 hours, so the 43.48% jump in RIBBR cannot be attributed to a specific announced event. The move likely reflects typical SPAC rights volatility or a technical catalyst unrelated to disclosed news.

Ribbon Acquisition Corp Rights is a SPAC rights offering, a security class known for extreme intraday volatility and outsized percentage swings on relatively small absolute dollar moves. A 43-cent gain represents a significant percentage return but may reflect modest dollar volume given the low share price. Without news headlines to anchor the move, the jump could stem from several typical sources for this security type: technical trading activity, options-related hedging, retail interest in low-priced securities, or delayed news not yet captured in financial feeds. SPAC rights often trade disconnected from fundamental catalysts and can spike on merger speculation, insider activity, or simply algorithmic trading patterns that amplify small share price changes into large percentage moves.

POET

POET Technologies Inc.Technology

$20.57+$6.20

+43.1%

NASDAQ · Mkt cap $1.5 B

POET Technologies announced a $50 million initial supply agreement with Lumilens for optical engines and a potential $500 million AI infrastructure deal, driving strong momentum in a stock already up over 100% in one month on AI hype.

The stock jumped 43% on May 14, 2026, following two major announcements: a supply and development partnership with Lumilens including a $50 million purchase order for high-speed optical modules, and news of a potential $500 million AI data center infrastructure deal. These concrete commercial milestones align with the broader surge in AI infrastructure and memory-related stocks highlighted in the same news cycle. Micron and similar semiconductor plays have benefited enormously from hyperscaler demand, and POET's optical networking components serve that same ecosystem. The company had already appreciated over 100% in one month, so the stock was primed for momentum; these announcements provided specific catalysts that justified acceleration. The timing coincides with Cisco reporting strong Q3 results, reinforcing sector-wide tailwinds for infrastructure vendors.

ATYR

aTyr Pharma, Inc.Healthcare

$0.56+$0.16

+41.4%

NASDAQ · Mkt cap $52 M

aTyr Pharma announced upcoming investor conference participation on May 13, which likely triggered the 41% gain by signaling management engagement and potential near-term visibility into company progress for shareholders.

The only headline provided is aTyr's announcement that it will participate in upcoming investor conferences. This is a relatively modest disclosure—it does not contain clinical trial results, regulatory approvals, partnerships, or forward guidance changes. However, for a clinical-stage biotech stock trading at $0.56, investor conference participation can serve as a positive signal that management is preparing to discuss recent developments or roadmap milestones. The truncated headline text suggests the company focuses on tRNA synthase technology and first-in-class drug candidates, areas that generate sector interest. A 41% single-day move on a conference participation announcement alone would be unusually large; more likely this reflects a combination of the news plus underlying technical factors (low liquidity, short covering, or accumulated positive sentiment that the announcement merely triggered). Without more detailed headlines, we cannot confirm whether specific clinical or business updates were included in the full press release.

GTBP

GT Biopharma, Inc.Healthcare

$0.44+$0.13

+40.4%

NASDAQ · Mkt cap $11 M

GT Biopharma announced the first patient dosed in a Phase 1 trial for GTB-5550, its solid tumor-targeting NK cell engager, marking clinical advancement and expansion into a broader market opportunity that drove the 40% single-day gain.

The company released two coordinated news items on May 14 announcing the dosing of the first patient in a Phase 1 dose-escalation basket trial for GTB-5550, a B7-H3-targeted natural killer cell engager designed for solid tumors. This represents a clinical milestone for a lead candidate and marks the company's third TriKE platform asset to enter human trials. The announcement explicitly frames this as an expansion into a broader solid tumor opportunity beyond the company's prior focus. For a small-cap biotech stock, first-patient-dosed announcements in Phase 1 trials typically drive positive sentiment, as they demonstrate pipeline progression, validation of the therapeutic approach, and reduction of execution risk. The timing and dual coverage suggest this was a material corporate event coordinated for maximum visibility.

TVGN

Tevogen Bio Holdings Inc.Healthcare

$9.42+$2.65

+39.1%

NASDAQ · Mkt cap $27 M

No news headlines were published in the last 48 hours, so the 39% gain is unexplained by reported corporate developments. The move likely reflects either a delayed market reaction to older news, technical trading, or an unannounced catalyst.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours rules out recent earnings announcements, regulatory approvals, clinical trial results, or partnerships as documented causes for this substantial intraday move. For a biotech firm like Tevogen Bio, typical catalysts include FDA decisions, clinical trial readouts, or strategic announcements. The magnitude of the gain (39%) suggests either a meaningful fundamental event occurred but has not yet been widely reported, or the move reflects technical factors such as short covering, options-related gamma activity, or accumulated retail momentum from earlier undisclosed news. Without access to the headline content before the 48-hour window or real-time trading data, attribution remains speculative.

IPST

IP Strategy Holdings, Inc.Consumer Defensive

$8.06+$2.26

+39.0%

IPWR

Ideal Power Inc.Technology

$7.38+$2.00

+37.2%

NASDAQ · Mkt cap $86 M

Ideal Power reported Q1 2026 results on 2026-05-14 highlighting commercial traction for its B-TRAN semiconductor technology in AI data centers and energy infrastructure, driving a 37% rally despite zero Q1 revenue and wider net losses.

The +37% move occurred on the same day as Ideal Power's earnings release and investor discussion. While headline-grabbing financial metrics were negative (no revenue, wider losses), management's narrative centered on accelerating commercial activity and positioning of its B-TRAN bidirectional switch technology for a major industry shift toward high-voltage DC power in AI data center infrastructure. For early-stage semiconductor and infrastructure technology companies, revenue and profitability are often secondary to evidence of growing commercial traction and market adoption, especially in high-growth segments like AI data centers. The three separate news items emphasizing "strong progress," "gaining traction," and strategic positioning in a major market shift suggest the market interpreted this call as validation of the technology's commercial viability despite near-term financial losses. This is consistent with how pre-revenue or low-revenue technology companies are valued.

FENC

Fennec Pharmaceuticals Inc.Healthcare

$9.24+$2.47

+36.5%

NASDAQ · Mkt cap $416 M

Fennec Pharmaceuticals beat Q1 earnings and revenue expectations on May 14, with PEDMARK sales jumping 73% year-over-year and the company achieving positive operating cash flow, driving a 36% single-day rally.

The headlines establish that Fennec reported first-quarter results that exceeded analyst forecasts on both earnings and revenue measures. Specifically, the company delivered a 157% earnings surprise and 8.36% revenue surprise, with total Q1 net revenues of $15.1 million, up 73% year-over-year. The key driver was strong PEDMARK sales growth, and management noted record demand for the product in April 2026 and early positive signals from field sales expansion. The company also swung to positive operating cash flow. The scale of the gain (36%) is notably larger than the modest premarket gains (3-12.6%), suggesting either delayed absorption of the results, options market positioning noted in one headline, or accumulating positive sentiment through the trading day as additional details circulated.

YOUL

Youlife Group Inc. American Depositary SharesConsumer Defensive

$1.13+$0.29

+34.5%

NASDAQ · Mkt cap $43 M

No news headlines were found in the last 48 hours, so the 34.52% gain likely reflects either a delayed market reaction to an earlier announcement, a short squeeze, technical trading, or an unindexed rumor or development in the microcap space.

The absence of any Yahoo Finance headlines in the 48-hour window preceding this gain makes it impossible to attribute the move to a specific corporate event like earnings, guidance, FDA approval, partnership, or M&A. For a NASDAQ-traded microcap security trading at $1.13, price moves of this magnitude can occur from several non-headline sources. The stock may have experienced a technical reversal or breakout following a period of consolidation, retail trading interest (particularly if it had accumulated short positions), or word-of-mouth activity in online forums that precedes or occurs outside traditional news channels. It is also possible that news was released on May 14 after market open or late on May 13 and has not yet been syndicated to the RSS feed. Without access to the underlying fundamental or technical catalyst, any explanation remains speculative.

TBH

Brag House Holdings, Inc.Technology

$0.86+$0.22

+33.6%

FCHL

Fitness Champs Holdings Limited Common StockConsumer Defensive

$2.68+$0.65

+32.0%

NASDAQ · Mkt cap $1.5 M

FCHL surged 32% on May 14 following a 53% intraday jump on May 13, though headlines reference only a recent public offering and pump-and-dump fraud allegations without explaining the specific catalyst for the rally.

The headlines document a sharp reversal in FCHL's price action on May 13, with the stock climbing 44% after-hours and then 53% intraday on May 13, extending into a 32% gain by May 14. However, the news items provided do not identify a discrete catalyst for this rally. The most recent substantive item mentions pump-and-dump fraud allegations and notes the stock had been among the worst performers in 2026 prior to the surge. An earlier headline references a $5 million best-efforts public offering priced on April 17, which would not explain a mid-May rally. For a micro-cap stock with a market cap under $2 million and trading at such low prices, rallies are often driven by technical factors including short squeezes, retail social-media attention, or unverified rumors rather than fundamental news. Without a specific announcement in the provided headlines, the cause remains unclear.

CAST

FreeCast, Inc. Class A Common StockCommunication Services

$1.86+$0.44

+31.0%

NASDAQ · Mkt cap $100 M

No news headlines were found in the last 48 hours, so the 31% gain on CAST likely stems from technical trading, a delayed announcement not yet picked up by Yahoo Finance RSS, or broader market sentiment toward small-cap stocks.

FreeCast is a microcap stock trading at $1.86 with significant intraday volatility typical of low-liquidity securities. The absence of any news headlines in the provided feed over the last 48 hours means we cannot attribute the move to a company-specific catalyst like earnings, guidance, a partnership announcement, or regulatory approval. For stocks in this market segment, large percentage moves often reflect technical rebounds from oversold conditions, short covering, small block trades moving the bid-ask spread substantially, or word-of-mouth interest spreading faster than formal news channels. It is also possible that a material announcement was made but not yet indexed by the RSS feed or picked up by Yahoo Finance within the measurement window. Without access to the company's investor relations page or real-time social media, attributing the move to a specific catalyst would be speculation.

TRT

Trio-Tech InternationalTechnology

$14.02+$3.28

+30.5%

AMEX · Mkt cap $114 M

Trio-Tech reported 124% Q3 revenue growth driven by strong demand for semiconductor reliability testing in AI and automotive applications, which directly triggered the 30.54% single-day surge.

The headline establishes a specific earnings announcement released on May 14, 2026 at 12:30 UTC showing exceptional revenue growth of 124% in Q3. This growth was explicitly attributed to increased demand for Trio-Tech's semiconductor back-end solutions, particularly for reliability testing supporting AI and automotive sectors—both high-growth markets. A revenue beat of this magnitude, combined with tailwinds from secular trends in AI and automotive electrification, provides clear fundamental justification for a substantial single-day jump. The timing of the announcement (midday) coincides with the stock ranking as the 27th biggest gainer, consistent with a positive earnings surprise triggering buy interest throughout the trading session.

ONEG

OneConstruction Group LimitedIndustrials

$1.10+$0.25

+29.4%

NASDAQ · Mkt cap $16 M

No news headlines were found in the last 48 hours, so the cause of ONEG's 29% gain cannot be determined from public announcements; the move likely reflects technical trading, delayed news publication, or unconfirmed market rumors.

The absence of any recent news headlines makes it impossible to attribute ONEG's strong 29% single-day gain to a specific catalyst. In such cases, moves in smaller-cap or lower-priced stocks often reflect technical factors such as short covering, options expiration effects, or algorithmic trading. Alternatively, material news may exist but has not yet been indexed by the news feed, or the market may be reacting to rumors or social media activity not captured in formal announcements. Without headline support, we cannot confirm whether this is driven by company-specific news (contract wins, operational updates, earnings) or broader market sentiment.

BNZI

Banzai International, Inc.Technology

$6.53+$1.48

+29.3%

NASDAQ · Mkt cap $5.6 M

Banzai announced a Q1 2026 earnings conference call scheduled for May 15, 2026, likely triggering anticipation ahead of results disclosure and investor optimism about the AI-powered sales technology company's performance.

The only news directly tied to Banzai is the announcement that the company will host its Q1 2026 financial results conference call on Friday, May 15, 2026 at 4:30 p.m. ET. This announcement came on May 12, and the stock jumped 29.31% the following day. The timing strongly suggests investors are positioning ahead of earnings. The other two headlines concern unrelated companies (Fluent and National CineMedia) and do not pertain to Banzai. Earnings announcements and conference calls often trigger significant moves as investors either front-run expectations or react to advance optimism in the sector. As an AI-powered sales and marketing technology firm, Banzai operates in a sector that has been favored by growth-oriented investors, which could amplify pre-earnings enthusiasm.

BOT

RoboStrategy, Inc. Common StockFinancial Services

$27.10+$6.09

+29.0%

NASDAQ · Mkt cap $665 M

BOT surged nearly 29% on May 14 after sharp selling pressure reversed course following its explosive Nasdaq debut and volatility halts earlier in the week, suggesting a technical rebound or renewed retail enthusiasm in a speculative stock.

The headline from May 13 describes sharp selling the day before as speculative enthusiasm faded post-debut, but it does not explain the subsequent 29% jump on May 14. The article is incomplete, cutting off mid-sentence, so we lack the full context of what triggered the initial enthusiasm or any catalysts announced on May 14. The most likely explanations are technical: a rebound after oversold conditions from the prior day's decline, short covering given the stock's apparent volatility and speculative nature, or renewed retail buying interest in a newly listed, high-momentum security. The multiple volatility halts mentioned suggest this is a highly volatile, thinly traded, or heavily speculated stock prone to mechanical rebounds. Without an actual news catalyst on May 14 provided in the headlines, the jump appears driven by technicals and sentiment rather than fundamental events.

TXXH

21Shares 2x Long HYPE ETF

$29.62+$6.57

+28.5%

NASDAQ

No news headlines were reported in the last 48 hours, but TXXH is a 2x leveraged long ETF on the HYPE index, so a broad rally in high-growth/speculative stocks would mechanically amplify gains by approximately double the underlying index move.

No headlines appeared in the Yahoo Finance RSS feed for the last 48 hours to point to a specific catalyst. However, TXXH's structure as a 2x long leveraged ETF means it magnifies daily moves in its underlying HYPE index by design. A 28.52% gain in the ETF suggests the underlying index rose roughly 14% or more, likely driven by broad strength in high-growth, speculative, or technology-adjacent equities. This could reflect a market rotation into risk, positive sentiment on growth stocks, declining rate expectations, or simply tactical buying in a volatile segment. Without news coverage, the cause remains inference based on the ETF's mechanics rather than confirmed event risk.

ORIS

ORIENTAL RISE HOLDINGS LtdConsumer Defensive

$0.54+$0.12

+28.0%

NASDAQ · Mkt cap $545 K

No news directly about ORIS was provided, so the 28% gain likely reflects sector momentum in consumer staples or a technical/micro-cap bounce, as the only headline references other consumer staples gainers moving sharply higher on the same day.

The news snippet provided does not contain any announcement specific to Oriental Rise Holdings. It only mentions that Edible Garden and Grocery Outlet gained 46% and 20% respectively on Wednesday after-market, suggesting broad strength in consumer staples that day. ORIS, trading at $0.54 with a micro-cap profile, may have participated in sector-wide momentum or benefited from technical buying pressure common in low-priced stocks. Alternatively, an ORIS-specific catalyst (earnings, regulatory filing, partnership, or insider activity) could have driven the move but is simply not captured in the provided headlines. Without direct news about ORIS itself, we cannot isolate the precise cause.

XCH

XCHG Limited American Depositary ShareIndustrials

$0.90+$0.19

+26.8%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours, so the 26.76% gain likely reflects a technical bounce, delayed market reaction to an older announcement, or retail buying activity unrelated to published company news.

The absence of recent headlines is notable for a stock jumping to the 33 biggest gainer spot on the day. This suggests the move was not driven by a fresh earnings report, regulatory action, merger announcement, or guidance change that would typically appear in financial news feeds. For a micro-cap American Depositary Share trading under $1, several alternative catalysts are plausible: a technical bounce after oversold conditions, delayed retail attention or social media activity, options expiration mechanics, or a reversal of prior day weakness. Without access to intraday volume, short interest data, or options activity, it is impossible to determine which mechanism drove today's move. The stock's low price and NASDAQ listing suggest it operates in a space where news dissemination may lag or where non-fundamental trading dynamics dominate.

LOCL

Local Bounti CorporationConsumer Defensive

$1.86+$0.39

+26.5%

NYSE · Mkt cap $25 M

Local Bounti reported Q1 2026 results with significant revenue growth and secured a $15 million investment, which likely drove the 26.5% gain on the earnings announcement and positive strategic update.

The timing of the price jump aligns directly with Local Bounti's earnings release and investor call on May 13. The headlines highlight two concrete positives: reported revenue growth in Q1 2026 and a newly secured $15 million investment that the company characterized as enhancing its strategic and financial outlook. For a smaller indoor agriculture company trading at $1.86, both revenue acceleration and fresh capital are material catalysts that can attract investor interest, particularly if the company had faced prior liquidity or growth concerns. The headlines do not provide specific revenue or earnings numbers, so we cannot verify whether results beat or missed consensus, but the framing as "significant revenue growth" suggests management presented the quarter positively. The $15 million capital raise is a concrete positive for a company likely managing tight margins.

ONDS

Ondas Holdings Inc.Technology

$11.21+$2.35

+26.5%

NASDAQ · Mkt cap $4.3 B

Ondas reported record Q1 2026 revenue of $50.1 million (a tenfold increase year-over-year) and raised full-year guidance to $390 million, triggering the 26.52% jump as investors reacted to accelerating defense, counter-drone, and autonomous systems demand.

The earnings release on May 14 established a clear catalyst: Q1 revenue of $50.1 million exceeded the company's own guidance by 25 percent and represented a 1,065 percent increase from Q1 2025. Management simultaneously raised its full-year 2026 revenue forecast to at least $390 million. Multiple headlines from the same day highlight growth across defense, counter-drone, surveillance, and autonomous systems markets, along with a surge in defense backlog. The stock's ranking as the 35th biggest gainer of the day is proportionate to the magnitude of the earnings beat and guidance raise. No contradictory news or material risks are evident in the provided headlines. The Palantir partnership mentioned in one headline adds credibility to the growth narrative but is not new information.

RXT

Rackspace Technology, Inc.Technology

$7.29+$1.52

+26.3%

NASDAQ · Mkt cap $839 M

No news headlines were found in the last 48 hours, so the 26.34% jump in RXT cannot be directly attributed to a disclosed event. The move likely reflects technical trading, short covering, or undisclosed market developments.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for RXT's strong 26.34% gain, which places it among the day's top 36 gainers. In cases where a stock experiences significant upward momentum without corresponding news, the move typically reflects one of several dynamics: short-squeeze activity where traders covering bearish positions drive rapid price appreciation, technical trading triggered by breaking through resistance levels or positive chart patterns, broader sector rotation into technology or cloud infrastructure names, or unannounced corporate actions. Rackspace Technology operates in cloud computing and managed hosting, sectors that can be sensitive to enterprise spending sentiment and competitive dynamics. Without access to intraday trading volume, options activity, or insider news, it is impossible to determine which of these mechanisms drove today's move.

IMDX

Insight Molecular Diagnostics Inc.Healthcare

$6.42+$1.32

+25.9%

NASDAQ · Mkt cap $143 M

IMDX surged 25.88% following Q1 2026 earnings results and GraftAssure commercialization progress announcements, including third-party data publications and a major U.S. transplant center signing on for clinical trials.

On May 13-14, IMDX released Q1 2026 earnings results alongside an explicit update on GraftAssure commercialization milestones. The headlines emphasize tangible progress: third-party head-to-head comparative data has been published, the GALACTIC registry study is advancing, and notably, a top-10 U.S. kidney transplant center has become the first to sign on for clinical trials. These are concrete commercial and clinical validation points for a molecular diagnostics company whose core product candidate is moving toward real-world adoption. The earnings call highlights also mention international expansion and regulatory progress, though the specifics are not detailed in the available snippets. For a small-cap diagnostics stock, signing a major transplant center as a first clinical partner and publishing third-party validation data represent meaningful de-risking events that justify investor enthusiasm.

AIAI

AIAI Holdings Corporation Class A Common StockIndustrials

$15.09+$3.09

+25.8%

NASDAQ · Mkt cap $367 M

AIAI Holdings began trading on NASDAQ on May 14, 2026 under ticker AIAI, which directly explains the 25.75% jump as a typical IPO first-day pop reflecting initial demand and market enthusiasm for the newly listed AI-focused company.

The headline confirms that AIAI Holdings Corporation launched trading on NASDAQ on the exact date of the price snapshot. The company positions itself as an AI implementation firm focused on real-world applications. First-day IPO pops of 20-30% are common when there is strong underwriter demand, limited float, and retail investor enthusiasm. The company's AI sector focus is particularly likely to attract speculative buying in 2026 given sustained market interest in artificial intelligence. The press release emphasizes "amplifying intelligence" and launching "a new era" which suggests classic IPO marketing framing. Without access to IPO pricing or the prospectus, we cannot determine whether the stock opened above its IPO price or how much of the move represents genuine valuation discovery versus typical first-day volatility, but the timing and magnitude are entirely consistent with standard IPO behavior rather than a dramatic fundamental catalyst.

QNTM

Quantum BioPharma Ltd.Healthcare

$6.87+$1.40

+25.6%

NASDAQ · Mkt cap $23 M

No news headlines were found in the last 48 hours, so the 25.59% gain in QNTM cannot be attributed to a specific disclosed event. The jump likely reflects either a delayed market reaction to an older announcement, technical trading activity, or undisclosed developments.

The absence of recent news headlines is notable given the magnitude of the intraday move. For a small-cap biotech stock like Quantum BioPharma, a 25% single-day gain typically correlates with material catalysts such as clinical trial results, FDA decisions, partnership announcements, or significant financing events. Since no such headline appears in the provided 48-hour window, several possibilities exist. First, the market reaction could be delayed response to an earlier announcement from more than 48 hours prior. Second, the move could reflect technical factors such as short covering, options-related gamma activity, or algorithmic trading in a low-liquidity name. Third, there may be an unconfirmed rumor or announcement circulating on alternative channels that has not yet reached major financial wire services. Without corroborating news, the specific catalyst remains unknown.

CHR

Cheer Holding, Inc.Communication Services

$1.94+$0.40

+25.6%

NASDAQ · Mkt cap $3.3 M

No news headlines were found in the last 48 hours, so the 25.57% gain cannot be directly attributed to a reported company announcement, earnings release, or regulatory action. The move likely reflects technical trading, short covering, or unreported developments.

With zero headlines available in the Yahoo Finance RSS feed for the past two days, we cannot pinpoint a specific catalyst for CHR's strong rally. Penny stocks and micro-cap securities like Cheer Holding often exhibit large intraday swings driven by factors other than fundamental news, including technical bounces from oversold levels, short squeeze activity if the stock has heavy short interest, retail trading momentum, or insider trading activity that precedes public disclosure. Without access to SEC filings, earnings calendars, or alternative news sources, we cannot rule out that a material event occurred but simply was not yet picked up by Yahoo Finance's feed. The 25.57% single-day move is consistent with low-float, low-liquidity stocks that can gap on modest volume.

CSCL

Direxion Daily CSCO Bull 2X ETF

$61.86+$12.52

+25.4%

NASDAQ

No news headlines were found in the last 48 hours, but CSCL is a 2X leveraged bull ETF tracking Cisco (CSCO), so a significant move in the underlying stock would be amplified roughly twofold, making a 25% jump consistent with an approximately 12-13% gain in Cisco itself.

The lack of recent headlines means we cannot identify a specific catalyst from news sources. However, CSCL's structure as a daily 2X leveraged bull ETF is directly relevant to understanding this move. The fund is designed to deliver twice the daily performance of the Nasdaq-100 Technology Sector, with heavy Cisco weighting. A 25% jump in the ETF is mechanically consistent with a material move in Cisco or the broader tech sector. This could reflect earnings results, analyst upgrades, sector rotation, or market-wide momentum that occurred but simply isn't captured in the headline feed provided. Cisco-specific catalysts (earnings, guidance, strategic announcements) or broader tech sector strength are the most likely categories, but without headline confirmation, we cannot pinpoint the specific driver.

AEHL

Antelope Enterprise Holdings LimitedIndustrials

$4.53+$0.91

+25.1%

NASDAQ · Mkt cap $6.5 M

No news headlines were found in the last 48 hours for AEHL, so the 25% gain likely reflects a delayed market reaction to an earlier announcement, technical trading, or untracked company-specific catalyst.

The absence of recent headlines in the Yahoo Finance RSS feed does not rule out the existence of news; it may indicate the story was published before the 48-hour window, covered by sources outside the RSS feed, or released after market close on May 13. A 25% single-day move in a lower-priced stock like AEHL can be triggered by earnings surprises, guidance revisions, contract announcements, insider buying, short squeeze activity, or index inclusion. Without access to the full news ecosystem or AEHL's recent corporate calendar, it is impossible to identify the specific catalyst. The rank as the 42nd biggest gainer suggests the move is substantial but not anomalous for the broader market that day.

HKIT

Hitek Global Inc.Technology

$0.87+$0.17

+24.7%

NASDAQ · Mkt cap $27 M

Hitek Global surged 24.74% on May 14 following the May 13 announcement that the company achieved a 124% revenue increase to $6.5 million in FY2025, reversing its prior status as a worst performer.

On May 13, Yahoo Finance reported that Hitek Global had posted strong FY2025 results with revenue climbing to approximately $6.5 million from $2.9 million in FY2024, representing substantial growth. This headline appeared just hours before the market open on May 14, providing the most straightforward explanation for the 24.74% rally. The news directly contradicts the earlier narrative that HKIT was "one of the worst performing NASDAQ stocks so far in 2026," suggesting a meaningful operational turnaround. The dramatic revenue growth likely attracted investors who had written off the stock. No offsetting negative news or caveats appear in the provided headlines, and the timing between the May 13 announcement and May 14 price action aligns well with typical market reaction patterns to earnings surprises.

IMRN

Immuron LimitedHealthcare

$1.11+$0.22

+24.7%

NASDAQ · Mkt cap $9.6 M

No news headlines were found in the last 48 hours, so the 24.72% gain lacks an identified catalyst. The move was likely driven by technical factors, retail trading activity, or undisclosed company news not yet indexed.

Immuron Limited experienced a significant single-day rally of nearly 25% with no corresponding news coverage available in the 48-hour window preceding the price action. This disconnect between magnitude of move and headline silence suggests several possibilities. First, the catalyst may exist but has not yet been picked up by major financial news aggregators. Second, the stock may have experienced technical buying pressure, short covering, or retail-driven momentum unrelated to fundamental news. Third, a small-cap biopharmaceutical stock like Immuron may have experienced a delayed market reaction to older news, an internal company announcement distributed through investor relations channels, or sector-wide momentum in immunology stocks. Without concrete news evidence, pinpointing the specific driver remains speculative.

LTRN

Lantern Pharma Inc.Healthcare

$3.13+$0.62

+24.7%

NASDAQ · Mkt cap $33 M

Lantern Pharma announced the closing of a $9.25 million registered direct offering on May 14, which likely drove the 24.7% gain as the capital infusion and institutional investor confidence boosted the stock.

Lantern Pharma announced on May 13 that it was launching a registered direct offering of up to $9.25 million with existing holders and an institutional investor. The company then announced the closing of that offering on May 14, the same day of the 24.7% price jump. For small-cap biotech and pharma companies, successful completion of a capital raise—especially one involving new institutional participation—often signals validation and provides liquidity for operations and clinical development. The timing between the closing announcement and the gain suggests investors viewed the offering positively as a vote of confidence and de-risking catalyst. However, the headlines do not specify the offering price, discount terms, or whether any clinical or operational developments accompanied the announcement, which limits understanding of why this particular raise resonated with the market on this particular day.

CPHI

China Pharma Holdings, Inc.Healthcare

$1.24+$0.24

+24.4%

AMEX · Mkt cap $44 M

China Pharma issued a statement acknowledging unusual market activity with no known cause, which paradoxically may have triggered or amplified the 24% intraday spike as traders reacted to the statement itself or underlying speculation.

The company's formal announcement that it is unaware of any events causing unusual trading activity is itself notable. This type of statement, often issued when a stock is moving sharply on no obvious news, can become self-fulfilling: the statement draws attention to the move, prompts retail traders and short-covering, and may validate existing speculation about undisclosed catalysts. Alternatively, the move could reflect delayed reaction to earlier developments not captured in the provided headlines, short-covering in a thinly traded micro-cap, or technical buying once the stock broke above resistance. China Pharma is a small-cap specialty pharma company listed on AMEX, making it susceptible to liquidity-driven rallies. Without headlines pointing to earnings, FDA action, partnerships, or guidance changes, the immediate cause remains unclear, though the statement confirms the company itself has no explanation.

BRUN

Boost Run Inc. Class A Common StockTechnology

$26.04+$5.04

+24.0%

NASDAQ · Mkt cap $1.4 B

Boost Run surged 24% likely due to an analysis published May 12 suggesting the company is on the verge of breaking even, signaling improved financial trajectory and reducing bankruptcy risk for this historically unprofitable business.

The single headline from May 12 indicates an analyst or financial publication assessed that Boost Run may be approaching profitability breakeven. For a company that has presumably operated at a loss historically, reaching breakeven represents a material inflection point—it demonstrates the business model is scaling toward sustainability and reduces tail risk of capital depletion. Investors often re-rate stocks sharply higher when a consistently unprofitable company shows credible signs of approaching profitability, as this removes a major overhang and suggests the path to positive earnings is becoming real rather than theoretical. The timing aligns well with the stock's 24% jump on May 14, two days after publication. However, the headline provides only the title and no detail about the specific metrics, timeframe, or confidence level of this breakeven analysis, so the exact nature of the catalyst remains partially obscured.

LGHL

Lion Group Holding Ltd.Financial Services

$0.94+$0.18

+23.8%

NASDAQ · Mkt cap $647 K

No news headlines were found in the last 48 hours, so the 23.85% gain likely reflects either a technical rebound, delayed disclosure of company news, or market speculation in a low-priced stock.

The absence of any Yahoo Finance headlines in the last 48 hours makes it impossible to attribute this move to a specific corporate event such as earnings, guidance, regulatory approval, or M&A activity. LGHL is a microcap trading at $0.94, a category where price action can be volatile and driven by factors beyond traditional news disclosure. Possible explanations include: (1) a technical bounce after prior weakness, (2) insider or institutional buying not yet reflected in public headlines, (3) a delayed announcement or filing that has not yet been indexed by news aggregators, or (4) retail or short-covering activity. Without headline confirmation or structural details about LGHL's business or market position, we cannot distinguish among these scenarios.

ALP

AlphaTON Capital Corp. Common StockFinancial Services

$0.33+$0.06

+23.2%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours to explain ALP's 23% gain, so the catalyst remains unclear; the move may reflect technical trading, delayed news circulation, or other market factors affecting this micro-cap stock.

AlphaTON Capital Corp. is a thinly-traded micro-cap stock, and no recent headlines are available to account for the substantial 23% intraday gain. In such securities, price moves of this magnitude often occur without immediately available news coverage. Possible categories of catalyst include delayed disclosure of earnings or corporate announcements that have not yet reached major wire services, technical buying driven by chart patterns or short covering in a low-liquidity name, insider activity or regulatory filings not yet indexed by news aggregators, or rumors circulating on social media or smaller forums. Without documented news or specific knowledge of the company's capital structure or insider ownership, we cannot distinguish between these hypotheses with confidence.

ATON

AlphaTON Capital Corp.Healthcare

$0.33+$0.06

+23.2%

NASDAQ · Mkt cap $667 K

No news headlines were found in the last 48 hours to explain ATON's +23% gain, so the driver remains unclear without additional context about company announcements, technical factors, or market rumors.

The absence of any news coverage in the last 48 hours makes it difficult to pinpoint a specific catalyst for the 23% rally in ATON stock. Given that ATON is a capital corporation (typically a blank-check or SPAC-related entity) trading at a low price point of $0.33, the move could stem from several categories of typical catalysts for such securities: a rumored or announced merger or business combination, short-squeeze activity given the low float and price, insider buying announcements, or updates on pending deals. Alternatively, the gain could reflect technical momentum, options-driven flows, or delayed dissemination of news not yet visible in the Yahoo Finance feed. Without seeing the actual news or company filings, attribution remains speculative.

Biggest Losers

Thu, May 14, 2026 50

TDIC

Dreamland Limited Class A Ordinary SharesCommunication Services

$0.80−$22.25

-96.5%

NASDAQ · Mkt cap $4.0 M

TDIC collapsed 96.53% on May 14, but available headlines from the prior 48 hours do not identify a specific catalyst, suggesting an undisclosed earnings miss, reverse split, delisting warning, or other material event not yet reflected in the news feed provided.

The two headlines from May 13 mention Dreamland (TDIC) only in passing as a stock "on investors' radars" alongside Oklo, Nextpower, SanDisk and Tesla, with no details whatsoever about the company, its financials, or any corporate action. The first headline concerns Harmonic Inc, an unrelated company. A 96% single-day collapse is typically triggered by catastrophic news: failed clinical trial, regulatory rejection, bankruptcy filing, failed merger, major insider selling, reverse split announcement, or a missed earnings report with sharply downward guidance. Without access to TDIC-specific breaking news from May 14 itself or late May 13, the true cause cannot be determined from the evidence at hand. Dreamland Limited appears to be a shell or micro-cap, which are prone to sharp moves on limited liquidity and minimal disclosure timing.

STAK

STAK Inc. Ordinary SharesEnergy

$0.88−$1.48

-62.7%

NASDAQ · Mkt cap $29 M

STAK reported fiscal H1 2026 results showing revenue growth but slowing profitability, triggering a sharp 62.71% intraday sell-off. The market repriced the stock downward after disappointing margin trends overrode top-line gains.

The headlines establish that STAK announced first-half 2026 financial results on May 13, which showed higher revenue but deteriorating profitability. One headline explicitly states shares fell nearly 39% in after-hours trading on May 13, and the intraday close on May 14 reflects a further cumulative decline to 62.71% total. The market's reaction was negative despite revenue growth, indicating that investor focus shifted to profitability contraction as the more material concern. The stock is in oilfield equipment, a cyclical sector sensitive to both commodity prices and capital spending patterns. Without the full financial details, we cannot determine whether margin pressure stemmed from rising costs, competitive pricing, operational challenges, or revised guidance, but the headline clearly links the selloff to the earnings announcement and the profitability slowdown it revealed.

WOK

WORK Medical Technology Group Ltd.Healthcare

$1.30−$1.46

-52.9%

NASDAQ · Mkt cap $5.2 M

WOK surged 69.67% in after-hours trading on Tuesday following a strategic disclosure by the Hangzhou medical device supplier, but collapsed 52.90% by the next trading day, suggesting either profit-taking, a reversal of enthusiasm once full details emerged, or negative follow-up news not yet captu…

The headline fragment indicates that WOK announced a strategic initiative on Tuesday that sparked a massive after-hours rally to $11.30, but the news text is truncated and does not reveal what the strategy actually was. By Wednesday's regular session close, the stock had crashed 52.90% to $1.30, a loss of nearly $10 per share. This dramatic reversal suggests either that investors rushed to take profits after the initial spike, that the full details of the announcement disappointed when disclosed, or that a negative development or corrective statement emerged between the after-hours surge and the next day's open. Without access to the complete announcement or any follow-up reporting from Wednesday, it is impossible to pinpoint the specific trigger for the collapse. The magnitude of both moves points to a material corporate event rather than technical factors alone.

MDXH

MDxHealth S.A.Healthcare

$0.98−$0.97

-49.5%

NASDAQ · Mkt cap $39 M

MDxHealth reported Q1 2026 earnings today showing revenue growth but announced a strategic exit from its Resolve UTI business and closure of its Plano laboratory, which triggered a 49.5% stock collapse as investors reacted negatively to the operational restructuring and implied margin pressure.

MDxHealth released Q1 2026 results on May 13-14 showing $27.4 million in revenue alongside positive commentary about growth and market leadership in precision diagnostics. However, the earnings announcement included two material operational changes: a strategic exit from the Resolve UTI testing business and planned closure of its Plano, Texas laboratory facility. While the headlines note robust revenue growth and describe the company as a leader in its space, the magnitude of the 49.5% stock decline suggests investors viewed the business exit and facility closure as indicators of either struggling unit economics, margin compression, or a broader pivot that undermines the prior growth narrative. The fact that operational losses are explicitly mentioned alongside revenue gains reinforces that profitability concerns likely drove the severe selloff. The restructuring may signal that growth alone is insufficient without path to profitability.

TOPS

Top Ships Inc.Energy

$0.95−$0.80

-45.7%

AMEX · Mkt cap $4.9 M

Top Ships Inc. dropped 45.70% on May 14, 2026, with no relevant news in the last 48 hours, suggesting the move was driven by technical selling, market sentiment shifts, or undisclosed corporate developments not yet reported.

No headlines from the last 48 hours are available to explain this sharp decline. Top Ships is a small-cap maritime shipping company trading on AMEX at a low stock price, which makes it susceptible to several typical catalysts: sector weakness in shipping rates or vessel values, liquidity concerns, debt covenant issues, insider selling, or technical breakdown below key support levels. Given the stock's micro-cap nature and the absence of reported news, this could also reflect a delayed market reaction to an event from earlier in the week, a private placement announcement, or deteriorating shipping fundamentals not yet formalized in press releases. Without confirmed news, attribution remains speculative.

YYAI

AiRWA Inc.Technology

$0.42−$0.26

-38.6%

NASDAQ · Mkt cap $3.9 M

AiRWA Inc. announced a 1-for-40 reverse stock split effective today, which mechanically reduces share price but does not change equity value; the 38.62% drop likely reflects market disappointment with the capital structure action itself, often associated with financial distress or dilution concerns.

The headline confirms that AiRWA implemented a previously stockholder-approved 1-for-40 reverse split on May 14, 2026. A reverse split mathematically reduces share price by the split ratio (in this case by a factor of 40), so a stock trading at approximately $16.80 before the split would trade around $0.42 post-split, consistent with the observed price. However, the stock is ranked the sixth biggest loser of the day, suggesting market sentiment is negative beyond the mechanical price adjustment. Reverse splits are commonly viewed as warning signals because companies resort to them when facing Nasdaq minimum bid price requirements, cash constraints, or strategic desperation. The magnitude of a 1-for-40 reverse split is notably aggressive, indicating the stock had fallen substantially before the split. Without additional headlines on earnings, guidance, or the reason for the split, the market's negative reaction appears to reflect underlying concern about company fundamentals rather than surprise about the split itself.

CHARR

Charlton Aria Acquisition Corporation

$0.08−$0.05

-37.8%

NASDAQ

No news headlines were found in the last 48 hours, so the 37.81% drop cannot be attributed to a specific disclosed event. For a blank-check SPAC trading at $0.08, the decline likely reflects either liquidation pressure, failed merger prospects, or redemption/dilution concerns.

Charlton Aria Acquisition Corporation is a SPAC (Special Purpose Acquisition Company), a structure designed to merge with an operating business. The stock's collapse to $0.08 with no accompanying headline suggests the market may be pricing in one of several SPAC-specific catalysts that do not always generate immediate news coverage. These include shareholder redemptions exceeding the sponsor's capital, an announced deal falling through or losing investor support, extension deadlines approaching without a merger target identified, or dilution from warrant exercises or sponsor equity grants. The absence of news combined with the severity of the move points toward structural SPAC risk rather than company-specific fundamentals, since SPACs have no operating business to report on. Without a specific announcement, we cannot confirm which of these pressures is at work.

RGNX

REGENXBIO Inc.Healthcare

$6.25−$3.80

-37.8%

FRGT

Freight Technologies, Inc.Technology

$0.61−$0.32

-34.3%

NASDAQ · Mkt cap $1.0 M

No news headlines were found in the last 48 hours, so the 34% drop cannot be attributed to a specific public announcement. The decline likely stems from technical selling, a delayed news event not yet reflected in the search, or sector-wide pressure in freight and logistics.

The absence of recent news headlines makes it impossible to pinpoint a direct catalyst for the sharp 34% decline in FRGT. Freight Technologies is a small-cap stock trading at $0.61, which typically exhibits higher volatility and can be sensitive to liquidity constraints or shifts in investor sentiment. Common drivers for this type of move in the freight or logistics sector include changes in freight rates, fuel costs, competitive pressures, or macroeconomic concerns about transportation demand. It is also possible that news was released but has not yet propagated to the headlines tracked in this search window, or that the move was driven by technical factors such as options expiration, stop-loss cascades, or reduced trading volume at market open. Without corroborating news, any specific explanation remains speculative.

HCAI

Hauchen AI Parking Management Technology Holding Co., Ltd.Industrials

$6.49−$3.37

-34.2%

NASDAQ · Mkt cap $7.9 M

No news headlines were found in the last 48 hours to explain HCAI's 34% drop, making the catalyst unclear without additional reporting on earnings, guidance, operational issues, or market conditions.

Yahoo Finance returned no recent headlines for HCAI in the 48 hours surrounding this move, which is notable given the stock's rank as the tenth-biggest loser of the day. A drop of this magnitude typically correlates with material negative news such as earnings misses, withdrawn guidance, loss of major contracts, regulatory setbacks, or management changes. Without headline evidence, the cause remains unconfirmed. For a NASDAQ-listed parking management and AI technology company, plausible explanations might include disappointing quarterly results if earnings were due, adverse regulatory developments in urban transit or smart city projects, or broader sector weakness in transportation or autonomous systems. This could also reflect a delayed market reaction to news that hasn't yet propagated through RSS feeds, or in extreme cases, company-specific crises announced directly without immediate press distribution.

LABT

Lakewood-Amedex Biotherapeutics Inc. Common StockHealthcare

$1.96−$0.99

-33.6%

NASDAQ · Mkt cap $3.8 M

No news headlines were available in the last 48 hours to explain the 33.56% drop in LABT, so the cause remains unknown, though biotech stocks commonly move sharply on clinical trial results, regulatory decisions, or financing announcements.

The absence of any news in the Yahoo Finance RSS feed over the last 48 hours means we cannot ground the explanation in a specific announced event. However, LABT is a biotherapeutics company, a sector highly sensitive to clinical, regulatory, and financial catalysts. Typical causes for sharp single-day declines in this space include negative trial data releases, FDA feedback or rejection letters, unexpected financing dilution, analyst downgrades, or insider selling. It is also possible the move reflects a delayed market reaction to a news item not yet indexed in the RSS feed, or execution of stop losses in a thinly traded stock. Without access to intraday news, trading halts, or SEC filings from May 14, we cannot pinpoint which of these categories applies here.

SBFM

Sunshine Biopharma, Inc.Healthcare

$0.47−$0.19

-28.9%

NASDAQ · Mkt cap $4.5 M

No news headlines were found in the last 48 hours, so the 28.90% drop cannot be directly attributed to a disclosed event. Biotech microcaps like SBFM are prone to sharp price swings on sector rotation, technical liquidation, or undisclosed catalysts.

The absence of any news in the Yahoo Finance RSS feed over the past two days makes it impossible to identify a specific announced catalyst for the decline. Sunshine Biopharma is a small-cap biotech firm trading at $0.47, a price point typical of development-stage or struggling pharmaceutical companies that often experience high volatility. Possible drivers include: (1) sector-wide biotech selloff or rotation out of small-cap names, (2) technical breakdown below a key support level triggering algorithmic or margin selling, or (3) company-specific news that has not yet been indexed by Yahoo Finance feeds, such as an internal announcement, clinical trial setback, or regulatory filing. Without access to company filings, press releases, or broader market context, the precise cause remains unknown.

EZRA

Reliance Global Group Inc.Financial Services

$0.11−$0.04

-26.5%

NASDAQ · Mkt cap $2.0 M

Reliance Global Group announced a 1-for-40 reverse stock split on May 14, which typically signals financial distress and often triggers sharp selloffs as existing shareholders face dilution pressure and delisting concerns.

The company announced a reverse stock split of 1-for-40 on the day of the price decline. While the headline provided does not explicitly state the rationale, reverse stock splits of this magnitude are commonly employed by companies facing NASDAQ minimum bid price requirements to avoid delisting. Shareholders typically view such actions negatively because they do not change underlying business fundamentals or total equity value; they mechanically compress share count while implying the stock has deteriorated below compliance thresholds. The 26.45% drop aligns with typical market reactions to reverse split announcements, which often reflect investor concerns about financial stability and future dilution. The stock's placement as 13 biggest loser suggests broad market recognition of the announcement as a negative signal.

LIVE

Live Ventures IncorporatedConsumer Cyclical

$10.24−$3.51

-25.5%

NASDAQ · Mkt cap $32 M

Live Ventures reported fiscal Q2 2026 results on May 14, triggering a 25.5% plunge, likely due to disappointing earnings, weak guidance, or operational setbacks within the diversified holding company.

The company announced its fiscal second quarter 2026 financial results on the day of the sharp decline. The headline confirms the earnings release occurred but provides no detail on whether results beat or missed expectations, what revenue or earnings figures were reported, or whether management issued forward guidance. For a diversified holding company with multiple business units, market disappointment typically stems from earnings misses, margin compression, deteriorating segment performance, or negative guidance revisions. The magnitude of the 25.5% drop suggests a material negative surprise rather than a minor miss. Without access to the actual earnings release details, we cannot identify which specific metric or business segment drove the selloff, but the timing correlation between the announcement and the plunge is direct and strong.

DOCS

Doximity, Inc.Healthcare

$18.01−$5.38

-23.0%

NYSE · Mkt cap $4.7 B

Doximity crashed 23% after reporting Q4 earnings that beat revenue but missed earnings expectations, coupled with weak fiscal 2027 guidance and multiple Wall Street downgrades citing AI spending pressures and slowing growth.

Doximity delivered a classic earnings disappointment: revenues exceeded estimates driven by AI tool adoption and customer growth, but earnings per share came in below expectations with margin compression from elevated AI infrastructure and development costs. The company then compounded the sell-off by issuing light guidance for fiscal 2027, signaling near-term growth deceleration. Multiple Wall Street analysts downgraded the stock the same day, citing concerns that while the company maintains its leadership position in the physician network space, the combination of industry-wide healthcare sector weakness and aggressive AI spending is creating a profitability headwind. The margin pressure and cautious outlook appear to have spooked growth-oriented investors who had priced in stronger near-term margins and guidance.

RVI

Robinhood Ventures Fund IFinancial Services

$57.27−$16.44

-22.3%

NYSE · Mkt cap $749 M

No news headlines were found in the last 48 hours to explain the 22.3% drop, making the precise catalyst unclear. The decline may reflect broad market weakness, fund valuation adjustments, or unreported developments affecting venture capital sentiment.

RVI is a closed-end venture fund with a portfolio dependent on mark-to-market valuations of private companies. With zero news in the recent window, the sharp decline likely stems from one of several structural factors typical for this asset class. First, venture-backed private companies may have faced valuation pressure or negative developments not yet surfaced in major news feeds. Second, broader market sentiment toward venture capital or growth equities may have deteriorated, causing discount widening or NAV compression. Third, the fund itself could have announced (on its own channels) a quarterly update showing portfolio markdowns or distribution changes. Finally, technical selling or rebalancing in the fund category is possible but harder to verify without more data. The 22% single-day move is substantial and suggests a material event, but its exact nature cannot be determined from available headlines.

PPCB

Propanc Biopharma, Inc.Healthcare

$0.07−$0.02

-21.4%

NASDAQ · Mkt cap $2.6 M

Propanc Biopharma announced a reverse stock split on May 13 to maintain Nasdaq listing compliance, a move that typically signals financial distress and often triggers sharp selling pressure as investors react to dilution concerns and delisting risk.

The headline confirms Propanc implemented a reverse stock split, a structural corporate action explicitly framed as necessary to "support continued Nasdaq listing." Reverse splits are generally perceived negatively by equity markets because they indicate a company has fallen below Nasdaq's minimum bid price requirement, signaling financial weakness. While the company frames this as supporting "growth plans," the market context is clear: without the split, delisting would have occurred. The 21.4% single-day drop is consistent with typical investor response to reverse split announcements in microcap biotech, where shareholders fear both further dilution and the reputational damage of near-delisting status. The stock's low absolute price of $0.07 post-announcement reflects the split-adjusted valuation.

ERNA

Ernexa Therapeutics Inc.Healthcare

$9.56−$2.58

-21.3%

NASDAQ · Mkt cap $5.2 M

No headlines were published in the last 48 hours explaining ERNA's 21.25% decline, so the specific catalyst remains unknown; the drop likely reflects either delayed news dissemination, technical selling, or clinical/regulatory developments not yet captured in major news feeds.

Ernexa Therapeutics is a small-cap biopharmaceutical company, and a sharp single-day decline of this magnitude without concurrent news coverage is not unusual in this sector. The lack of headlines in the 48-hour window could indicate several possibilities: the news may have broken outside the tracked RSS feeds, the market may be reacting to delayed or rumored information, or selling pressure could be driven by technical factors, sector rotation, or broad market conditions. Biotech stocks are particularly sensitive to clinical trial results, regulatory decisions, financing news, and management changes, any of which could trigger a move of this size even before formal announcements reach mainstream financial news. Without access to earnings reports, SEC filings, or company press releases from the snapshot date or immediately prior, attributing causation would be speculation.

EURKR

Eureka Acquisition Corp

$0.34−$0.09

-21.2%

MVIS

MicroVision, Inc.Technology

$0.60−$0.16

-21.1%

NASDAQ · Mkt cap $42 M

MicroVision reported Q1 earnings today with narrower losses, higher sales, and strategic LiDAR progress, but the stock still fell 21% despite early positive headlines citing a 16% intraday gain, suggesting sell-the-news weakness or disappointing guidance overshadowed the operational improvements.

The news cycle shows MicroVision announced Q1 2026 results with tangible improvements: sales grew 59% year-over-year to $935k, net loss narrowed to $25.29 million, gross margins expanded, and the company closed a $38.63 million shelf offering while announcing new Avular drone deals and commercial traction from Scantinel and Luminar LiDAR assets. Headlines from the morning and early afternoon indicate the stock initially rallied 16% on these results. However, the end-of-day snapshot shows a 21% loss, ranking it among the day's worst performers. This divergence suggests either heavy selling pressure into the strength, disappointing forward guidance provided during the earnings call that wasn't fully captured in the headlines reviewed, or a broader market rotation away from speculative LiDAR plays. The shelf offering might also have triggered dilution concerns. Without access to the full earnings call transcript details or guidance changes, the exact catalyst for the reversal remains partially obscured.

IVVD

Invivyd, Inc.Healthcare

$1.16−$0.31

-21.1%

NASDAQ · Mkt cap $283 M

Invivyd reported Q1 2026 earnings that missed revenue estimates by 25.3% and posted a 62.5% negative earnings surprise, triggering the 21% stock decline on disappointing financial performance despite modest PEMGARDA revenue growth.

Invivyd released Q1 2026 financial results on May 14 that fell substantially short of market expectations. While the company achieved PEMGARDA net product revenue of $13.7 million representing 22% year-over-year growth, this was offset by a significant revenue miss of 25.3% relative to consensus estimates and a severe earnings miss of negative 62.5%. The earnings call highlighted continued progress in the COVID-19 antibody program and elevated clinical spending tied to VYD2311 development, but investors appear to have focused on the magnitude of the earnings and revenue shortfalls rather than the pipeline developments. For a clinical-stage biotech company with limited approved product revenue, a quarter that misses expectations by this margin typically signals concerns about market traction, burn rate management, or updated financial guidance that disappointed the Street.

DGNX

Diginex LimitedIndustrials

$0.95−$0.25

-20.8%

NASDAQ · Mkt cap $37 M

Despite announcing a billion-dollar AI deal, $100M+ in acquisitions, and a $25.4M founder investment at 4.7x the current price, DGNX fell 20.83%, suggesting the market either viewed the terms as dilutive, the valuation claims as inflated, or was disappointed by execution details.

The timing is counterintuitive: the headline announced major strategic wins including a $40M reseller agreement, a $9.6B market opportunity, and notably a founder cash injection at much higher valuations. These are typically positive signals. However, the massive gap between the $4.70 entry price mentioned and today's $0.95 implies severe shareholder dilution or market skepticism about the deal's viability. The stock's ranking as the 22nd biggest loser suggests broad selling pressure rather than isolated profit-taking. Possible explanations include: the market interpreting the founder's discount entry as a red flag about current share quality, concerns about whether the AI deal or acquisition targets will deliver promised synergies, or unfavorable dilution terms that outweighed the strategic headlines.

ADTX

Aditxt, Inc.Healthcare

$0.07−$0.02

-20.7%

NASDAQ · Mkt cap $2.3 M

Aditxt announced a 1-for-27 reverse stock split effective May 18, which typically signals financial distress and dilution concerns, likely triggering the 20.67% single-day drop.

The company announced a reverse stock split at a 1-for-27 ratio, a move commonly associated with stocks trading below exchange minimum price requirements or used to consolidate shares when a company faces liquidity or operational challenges. Reverse splits are often viewed negatively by the market because they do not change the underlying business value or market capitalization, merely the share count and price per share. Investors frequently interpret such announcements as a red flag indicating the company is struggling to maintain listing standards or is attempting to artificially prop up its share price. The stock's current price of $0.07 before the split suggests it was trading at extreme penny-stock levels, which compounds concerns about company viability. The timing of the announcement alongside the sharp decline suggests market participants were already skeptical or reacting to the implicit signal the reverse split sends about the company's financial health.

MEI

Methode Electronics, Inc.Technology

$11.02−$2.86

-20.6%

NYSE · Mkt cap $546 M

MEI surged 34% on May 13 but collapsed 20.58% on May 14, suggesting the prior day's rally was either reversed by profit-taking, a negative news event, or technical unwinding without clear causal evidence in the provided headlines.

The available headlines document only that MEI shares rallied 34.1% to $12.55 during May 13's session, attributed vaguely to being among stocks moving in the intraday session. However, no specific catalyst for that gain is disclosed, and critically, no headlines explain the subsequent 20.58% drop on May 14. The reversal could reflect several mechanisms: profit-taking after an unexplained spike, a delayed negative announcement not yet captured in the RSS feed, earnings miss or guidance cut that occurred after May 13 close, a contract loss or customer issue, or technical mean reversion if the prior day's move lacked fundamental backing. Without additional news from May 13 PM through May 14, we cannot identify the trigger. This two-day pattern resembles a short-squeeze unwind or a rumor-driven spike followed by fact-checking, but both are inference rather than evidence.

HIT

Health In Tech, Inc.Technology

$1.23−$0.31

-20.1%

NASDAQ · Mkt cap $66 M

Health In Tech reported Q1 2026 earnings showing revenue growth but a wider loss due to intentional increased investment in sales and technology, disappointing investors expecting near-term profitability.

The three news headlines all relate to HIT's Q1 2026 earnings announcement on May 13-14. The company reported revenue growth alongside a widening net loss, attributed to management's deliberate decision to increase spending on sales distribution, carrier relationships, and technology development. This is a classic growth-at-expense-of-profitability scenario that often triggers sell-offs in early-stage or unprofitable tech companies, particularly in the InsurTech space where investor patience for losses can be limited. The stock ranked 25th among daily losers, suggesting the market viewed the earnings negatively. Without access to the full earnings transcript or specific guidance changes, we cannot determine whether the loss widening exceeded expectations, whether management cut forward guidance, or whether the investment thesis simply disappointed a primarily profit-focused investor base, but the timing and magnitude of the decline align tightly with the earnings release.

APACR

StoneBridge Acquisition II Corporation Rights

$0.12−$0.03

-20.0%

OFAL

OFA GroupIndustrials

$0.58−$0.14

-19.4%

NASDAQ · Mkt cap $2.5 M

OFA Group announced a $7.5 million tokenization platform services agreement for a Florida residential project on May 14, but the stock fell 19.43% the same day, suggesting market skepticism about the deal's value or near-term revenue impact rather than enthusiasm for the contract win.

The headline announces what appears to be a concrete business development win—a $7.5 million agreement for tokenization services related to a real estate project in Vero Beach, Florida. On the surface, a named contract of this magnitude should be neutral to positive for a micro-cap technology and real estate company. However, the timing of the announcement coinciding with a severe single-day decline suggests either that the market had priced in or expected a larger deal, that investors are skeptical about OFA's ability to execute or recognize revenue from this agreement, or that the underlying tokenization/digital asset infrastructure narrative has fallen out of favor with investors. The 19.43% drop ranks this as the 27th-biggest loser for the day, indicating sector-wide or stock-specific pressure beyond just this deal. Without additional market context or competing headlines, the most likely inference is that the announcement itself disappointed relative to expectations, or that broader sentiment toward speculative fintech and tokenization plays has deteriorated.

ENHA

A Paradise Acquisition Corp.Consumer Defensive

$4.26−$1.02

-19.3%

NYSE · Mkt cap $252 M

A Paradise Acquisition Corp (ENHA) fell 19.32% despite announcing Alan Walker as headliner for the Enhanced Games opening concert, suggesting the market either viewed the entertainment news as insufficient catalyst or reacted to unrelated negative developments not captured in the provided headlines.

The single headline available announces a positive event—a globally recognized artist headlining the Enhanced Games opening concert—which would typically support a stock price or at minimum not explain a severe 19% decline. This mismatch between bullish entertainment news and steep losses indicates either the market did not view the Alan Walker announcement as material, or more likely, other negative catalysts drove the move that are not represented in the Yahoo Finance RSS snapshot provided. For a SPAC-derived company like Enhanced, common sell triggers include dilution concerns, insider selling, missed milestones, cash burn worries, or competitive pressures in the longevity/sports sectors. The headline timing (12:59 UTC on the same day as the 19% drop) suggests the announcement may have been intended as a positive, but failed to offset broader headwinds affecting the stock that day.

LKSPR

Lake Superior Acquisition Corp. – Rights

$0.81−$0.19

-19.2%

NASDAQ

No news headlines were published in the last 48 hours, so the 19% drop in LKSPR rights cannot be directly attributed to a specific event. The decline likely reflects broader SPAC market weakness or deterioration in the underlying acquisition target's prospects.

Lake Superior Acquisition Corp. rights (LKSPR) are a leveraged claim on the SPAC's future merger economics, making them highly sensitive to deal sentiment and market conditions. With zero news coverage in the past two days, the sharp decline appears disconnected from a named catalyst. SPAC rights are prone to sharp moves driven by (1) negative sentiment toward the sponsor or target company that doesn't always generate immediate headlines, (2) deterioration in deal terms or timing expectations, (3) technical redemption pressure as the merger deadline approaches, or (4) broader SPAC market de-risking. Without access to company filings, merger vote outcomes, or insider activity in the past 48 hours, it is impossible to determine which of these categories drove the move.

WTF

Waton Financial Limited Ordinary SharesFinancial Services

$3.36−$0.79

-19.0%

NASDAQ · Mkt cap $140 M

No news headlines were available in the last 48 hours, so the cause of the 19% drop cannot be directly attributed to a specific event. The decline likely stems from technical selling, market-wide weakness, or untracked news outside the Yahoo Finance RSS feed.

The absence of recent headlines makes it impossible to pinpoint a specific catalyst for WTF's sharp 19% decline on May 14, 2026. For a financial services stock losing nearly one-fifth of its value in a single day, typical culprits would include earnings disappointment, regulatory action, credit rating downgrade, material insider departure, or significant market stress in the financial sector. Since no such announcements appear in the available news feed, the move could reflect delayed reaction to older developments, technical breakdown triggered by a broader market selloff, trading volume concentration on a low-float security, or news that simply did not appear in the Yahoo Finance RSS source monitored. Without access to additional data sources, platforms, or company filings, attribution remains speculative.

INVZ

Innoviz Technologies Ltd.Consumer Cyclical

$0.75−$0.17

-18.5%

NASDAQ · Mkt cap $107 M

Innoviz reported Q1 2026 revenue of $7.1 million, missing estimates by 47.63% and posting a significant earnings miss, which triggered the 18.53% sell-off despite management reaffirming full-year guidance and highlighting defense market opportunities.

Innoviz held its Q1 earnings call on May 14, 2026, and the results were materially weak. The company generated $7.1 million in revenue, falling sharply short of analyst expectations by nearly 48 percent. Earnings per share also missed by 66.67 percent. While management reaffirmed its full-year 2026 revenue outlook and emphasized emerging opportunities in defense, homeland security, and autonomous vehicles, the severity of the quarterly revenue miss and year-over-year revenue decline outweighed the forward-looking narrative. The stock market typically reprices sharply on earnings surprises, especially misses of this magnitude, and the depth of the shortfall relative to consensus estimates likely explains the significant single-day decline. The strategic commentary about new markets may have limited the damage but was insufficient to offset the disappointing current results.

NIQ

NIQ Global Intelligence PlcTechnology

$8.20−$1.84

-18.3%

NYSE · Mkt cap $5.6 B

NIQ reported earnings that beat expectations and reaffirmed guidance, but investor concerns about competitive risks emerged during or after the call, causing a sharp reversal from early premarket gains to an 18% decline by close.

The timeline reveals a classic intraday reversal. NIQ announced Q1 2026 results that exceeded analyst expectations and initially rallied 4.6% in premarket trading on May 14. However, by the afternoon, sentiment flipped sharply negative. One headline explicitly states the quarterly report "didn't do enough to assuage concerns about competitive risks," suggesting that while headline numbers beat, the details or forward commentary revealed competitive pressures the market found troubling. The earnings call summary was published after market close, so detailed investor concerns likely crystallized during the call itself or in analyst reactions immediately after. The 18% intraday swing indicates this was driven by sentiment shift during the trading day rather than overnight news.

LWLG

Lightwave Logic, Inc.Basic Materials

$14.93−$3.29

-18.0%

NASDAQ · Mkt cap $789 M

Lightwave Logic dropped 18% despite hitting an all-time high the prior day after reporting Q1 earnings with wider losses, modest revenue growth, and continued unprofitability, triggering a sharp sell-off in a pre-revenue or early-stage tech stock.

The company reported first-quarter 2026 results showing a wider net loss alongside only modest revenue growth. The earnings call highlighted progress on customer prototyping, foundry integration, and commercialization of electro-optic polymer technology for AI optics applications. However, the market's initial enthusiasm—evidenced by the stock hitting an all-time high on Wednesday ahead of earnings—appears to have reversed sharply once actual numbers were disclosed. The gap between investor expectations set by the prior day's rally and the reality of continued operating losses with limited near-term revenue trajectory likely triggered profit-taking and reassessment. Early-stage semiconductor and photonics companies are highly sensitive to execution milestones and path-to-profitability signals; a miss on market expectations despite operational progress can cause rapid reversals.

INVE

Identiv, Inc.Industrials

$3.96−$0.86

-17.8%

NASDAQ · Mkt cap $69 M

Identiv beat Q1 revenue guidance and reported strong operational progress, but missed earnings estimates and likely issued cautious forward guidance or signaled margin pressure, triggering the 17.84% sell-off despite the headline beat.

The news shows Identiv reported Q1 revenue ahead of guidance (up 7.44%) and highlighted progress on manufacturing transitions and strategic initiatives, which normally would support the stock. However, the company delivered an earnings surprise of negative 7.14%, meaning it missed EPS estimates despite the revenue beat. This earnings miss, combined with the typical market penalty for missing bottom-line targets even with a top-line beat, appears to be the primary driver. The headlines indicate the company is in transition phases (manufacturing shift, BLE smart-label rollout, strategic review) which may suggest near-term margin headwinds or execution risk. Investors often react more sharply to EPS misses than revenue beats because profits matter more for valuation. The sell-off intensity suggests either weak guidance for Q2-Q3 or management commentary signaling tougher conditions ahead, neither of which is explicitly detailed in the available headlines.

MGIH

Millennium Group International Holdings LimitedConsumer Cyclical

$1.48−$0.31

-17.3%

NASDAQ · Mkt cap $17 M

No news headlines were found in the last 48 hours for MGIH, so the 17.32% drop cannot be attributed to a specific announced catalyst; the cause remains unclear without additional market information.

The absence of any headlines in the search results means there is no publicly documented news event to explain the decline. For a micro-cap stock like MGIH trading at $1.48, price drops of this magnitude can be triggered by several categories of events: insider selling or lockup expiration, a delayed earnings miss or guidance cut announced outside major news feeds, short-squeeze unwind, sector rotation out of small-cap equities, liquidity concerns, or announcement via the company's own channels rather than major financial media. Without access to earnings releases, regulatory filings, or direct company announcements posted to the stock exchange, it is not possible to identify the specific driver. The lack of headline coverage itself could suggest either that the move is driven by technical or sentiment factors rather than fundamental news, or that the news has not yet been picked up by major wire services.

BTGO

BitGo Holdings, Inc.Financial Services

$9.86−$2.05

-17.2%

NYSE · Mkt cap $883 M

BitGo reported Q1 2026 earnings with 112.6% revenue growth but a widened net loss of $60.7 million due to Bitcoin writedowns and higher operating expenses, missing EBITDA expectations despite analyst support for the business model.

BitGo's earnings release on May 13-14 revealed a classic growth-versus-profitability disconnect. Revenue surged 112.6% year-over-year to $3.77 billion, yet the company posted a net loss that expanded to $60.7 million, primarily from Bitcoin accounting writedowns and elevated operating costs in a softer digital asset market environment. KBW maintained a $12 price target (23% above current price) and raised full-year 2026 revenue guidance, while Wedbush highlighted stable revenue opportunities from stablecoins, staking, subscriptions, and derivatives. The market appears to have focused on the bottom-line loss and EBITDA miss rather than the strong top-line growth or forward guidance, suggesting investor disappointment with near-term path to profitability despite structural business strength.

ODVWZ

Osisko Development Corp. Warrant expiring 5/27/2027Basic Materials

$0.13−$0.03

-16.7%

NASDAQ

The warrant's 16.72% decline cannot be clearly attributed to the Sarah MacDonald appointment announced on May 13, which is a routine operational hire with no obvious market-moving implications. The drop likely reflects broader market conditions, warrant decay, or underlying ODV equity weakness no…

The only recent headline is a personnel announcement regarding Sarah MacDonald joining as VP of Construction Contracting at Osisko Development, dated May 13. This is a standard operational staffing decision with no material business impact disclosed—no contract win, no production update, no financing event, and no guidance change. Warrant prices are sensitive to multiple factors beyond company news: time decay as expiration approaches (May 27, 2027 is about one year out), movements in the underlying ODV equity, implied volatility changes, and broader gold sector sentiment. The -16.72% move on the warrant likely stems from weakness in the parent company stock or a shift in volatility rather than the MacDonald appointment itself. Without ODV equity price data or gold market context from May 14, attributing the warrant decline to the headline would be speculative.

BATL

Battalion Oil CorporationEnergy

$2.10−$0.42

-16.7%

YIBO

Planet Image International Limited Class A Ordinary SharesTechnology

$0.74−$0.14

-15.9%

NASDAQ · Mkt cap $78 M

No news headlines were found in the last 48 hours, so the 15.91% drop cannot be attributed to any disclosed event. The decline likely stems from technical selling, market sentiment, or undisclosed developments.

The absence of any recent news makes it impossible to pinpoint a specific catalyst for YIBO's sharp 15.91% decline on May 14, 2026. Stocks in this price range and market cap typically experience volatility from several sources including algorithmic or technical selling following resistance breaks, shifts in sector sentiment, changes in short interest dynamics, or company-specific developments that may not yet be reflected in major news feeds. Without contemporaneous headlines, we cannot distinguish between a coordinated selloff driven by broader market conditions, a delayed earnings miss or guidance warning, insider activity, or other non-public information that may have triggered institutional or retail liquidation. The rank as the 39th biggest loser suggests moderate trading volume participation in the decline.

PYXS

Pyxis Oncology, Inc.Healthcare

$2.21−$0.41

-15.6%

NASDAQ · Mkt cap $214 M

Pyxis reported Q1 2026 results and MICVO clinical data on schedule for mid-year 2026, but the lack of any positive surprise or material acceleration appears to have disappointed the market, triggering a 15.65% sell-off in this clinical-stage biotech stock.

Pyxis announced first quarter 2026 financial results alongside an update on its lead program MICVO, confirming that Phase 1 monotherapy data in recurrent/metastatic head and neck squamous cell carcinoma remains on track for a mid-year 2026 update. The headlines indicate the company is meeting its existing timeline rather than announcing an acceleration, expansion of indications, or material efficacy breakthrough. For clinical-stage oncology companies trading on pipeline progress, the market often reprices sharply when updates meet but do not exceed expectations. The 15.65% drop suggests investors were pricing in either a more positive data readout or accelerated milestone timing. Without access to the full earnings call, Q1 cash position disclosures, or any guidance changes, the sell-off appears driven by the absence of positive surprise rather than a specific negative event, which is a common pattern for pre-commercial biotech firms dependent on clinical milestone sentiment.

AIRO

AIRO Group Holdings, Inc. Common StockIndustrials

$6.62−$1.22

-15.5%

NASDAQ · Mkt cap $271 M

AIRO reported Q1 revenue declines year-over-year despite reaffirming full-year guidance and highlighting a $150M+ defense backlog, likely disappointing investors who expected growth momentum to already be evident in near-term results.

AIRO released first-quarter 2026 earnings on May 14, 2026, showing revenue declines from the prior year. While management characterized results as in line with expectations and reaffirmed full-year revenue growth guidance, the market appears to have sold off sharply on the actual quarterly miss. The company did announce positive forward signals including an expanding AI-enabled drone portfolio and a defense backlog exceeding $150 million, but these longer-term catalysts were insufficient to offset investor disappointment at near-term revenue contraction. This is a common pattern: when a company telegraphs challenges ahead of results, the stock may still decline sharply on the miss itself, even if guidance remains intact. The 15.52% single-day drop suggests the magnitude of the revenue decline or margin pressure exceeded what the market had already priced in.

DTSQR

DT Cloud Star Acquisition Corporation

$0.11−$0.02

-15.4%

NASDAQ

No news headlines were available in the last 48 hours to explain the 15.45% decline in DTSQR. The drop is most likely attributable to technical selling, sector rotation, or deteriorating sentiment toward blank-check acquisition vehicles.

Despite a significant single-day loss ranking DTSQR among the top 42 losers on NASDAQ, no news events are documented in the available sources over the past two days. For a SPAC or shell company like DT Cloud Star Acquisition Corporation, typical catalysts for sharp declines include loss of investor confidence in management or the proposed merger target, dilution from secondary offerings or warrant exercises, insider redemption activity, regulatory pressure on blank-check structures, or simply broader market sentiment shifting against pre-revenue or speculative acquisition vehicles. Without access to company filings, social media commentary, or proprietary market data, attributing this move to any specific catalyst would be speculation. The absence of news does not rule out private developments or technical factors like end-of-day liquidation.

ISSC

Innovative Aerosystems, Inc.Industrials

$17.41−$3.18

-15.4%

NASDAQ · Mkt cap $330 M

Innovative Aerosystems reported Q2 fiscal 2026 earnings today with modest revenue growth but a sharp decline in F-16 defense revenue, likely triggering the 15.44% sell-off as investors reacted negatively to the defense segment weakness.

The company released second quarter results on May 14, 2026, showing mixed performance. While commercial aerospace and business aviation segments demonstrated strength, the headlines explicitly highlight a "sharp year-over-year decline tied to the F-16" program. This defense revenue contraction appears to have outweighed gains elsewhere and was significant enough to concern the market. The stock ranks as the 43rd biggest loser of the day, suggesting institutional selling followed the earnings release. Without access to the full earnings call transcript, guidance statements, or margin trends, we cannot determine whether the decline reflects disappointing guidance, margin compression, or simply a reassessment of the company's defense exposure and future revenue mix. The magnitude of the drop suggests the F-16 decline was either unexpected or more severe than the market had priced in.

SMTK

SmartKem, Inc.Technology

$0.23−$0.04

-15.4%

NASDAQ · Mkt cap $2.2 M

No news headlines were found in the last 48 hours to explain SmartKem's 15.42% drop on May 14, 2026, so the cause remains unclear without additional context.

The absence of any news headlines in the last 48 hours makes it impossible to identify a specific catalyst for this move. SmartKem is a small-cap semiconductor materials company, and stocks of this profile are typically sensitive to a range of catalysts including clinical or product development setbacks, cash burn concerns, dilutive financing announcements, analyst downgrades, shifts in industry sentiment, short covering reversals, or broad sector rotation out of high-risk equities. Without access to company filings, trading data, or news from other sources beyond the provided Yahoo Finance RSS feed, any explanation would be pure speculation. The timing and magnitude suggest something material occurred, but we simply lack the evidence to determine whether it was company-specific bad news, sector headwinds, or technical selling.

ALMU

Aeluma, Inc.Technology

$26.65−$4.84

-15.4%

NASDAQ · Mkt cap $325 M

Aeluma reported a swing from profitability to a net loss of $1.8 million in Q3 2026 despite revenue growth, disappointing the market even as the company secured new contracts and partnerships in the high-growth photonics space.

Aeluma announced Q3 fiscal 2026 results showing sales of $1.22 million but a net loss of $1.8 million (versus prior profitability), with basic loss per share of $0.10. While the company simultaneously announced over $4 million in new contracts, a NASA award, and partnerships with Tower Semiconductor and Sumitomo Chemical in the strategically important quantum dot laser and AI data center optical markets, the market punished the profitability reversal. The earnings call highlighted strong demand tailwinds from AI infrastructure investment straining optical component supply chains, suggesting future growth potential, but current-quarter losses outweighed forward-looking positives. This is a classic case where near-term financial deterioration dominates sentiment despite credible longer-term catalysts.

SKK

SKK Holdings LimitedIndustrials

$3.39−$0.61

-15.3%

NASDAQ · Mkt cap $14 M

No news headlines were available in the last 48 hours, so the 15.25% drop likely reflects either a delayed market reaction to an unreported event, broad sector weakness, or technical selling pressure.

The absence of any financial news in the RSS feed for SKK Holdings in the last 48 hours makes it impossible to attribute this significant decline to a specific catalyst. For a NASDAQ-listed stock dropping over 15% in a single day, the most common explanations fall into a few categories: either a material announcement occurred but was not yet captured in the news feed, or the move reflects broader sector headwinds affecting similar companies, or it stems from technical factors such as a stop-loss cascade or short covering. Without access to company filings, earnings calendars, or real-time news beyond the provided feeds, we cannot determine which mechanism is at work. The stock's rank as the 46th biggest loser suggests it is part of a wider selloff rather than an isolated event, which slightly favors a sector or market-wide explanation over company-specific news.

SOBR

SOBR Safe, Inc.Technology

$1.52−$0.27

-15.1%

NASDAQ · Mkt cap $1.6 M

No news headlines were available in the last 48 hours for SOBR, so the 15% decline likely stems from technical selling, sector rotation, or delayed market reaction to an earlier unobserved event.

SOBR Safe, Inc. experienced a sharp single-day loss of 15.08% with no corresponding news coverage in the last 48 hours according to the provided RSS feed. This disconnect between significant price action and absent headlines is not uncommon for smaller-cap stocks, which often trade on technical factors, retail momentum shifts, or reactions to news that may not be immediately indexed by major financial news aggregators. Without knowing SOBR's business model details, recent earnings dates, or current market sentiment toward its sector, reasonable hypotheses center on technical breakdown (support level broken, options expiration effects), sector headwinds affecting small-cap safety or tech companies, or a delayed negative catalyst from prior announcements that the RSS feed did not capture.

CTEV

Claritev CorporationHealthcare

$23.47−$4.11

-14.9%

NYSE · Mkt cap $662 M

CTEV fell 14.90% on May 14 despite announcing a new product launch (PHCS Novera) on May 13, suggesting the market either viewed the announcement negatively, expected better news, or the drop was driven by a separate unannounced catalyst not captured in the provided headlines.

The only recent headline is a product launch announcement from May 13, which is typically considered a positive or neutral event for a healthcare technology company. The timing suggests investors may have disappointed by the specifics of the PHCS Novera platform or competitive positioning, though the full press release text is truncated and does not explain investor reaction. Alternatively, the stock decline may be entirely unrelated to this announcement and driven by broader market factors, sector rotation out of healthcare IT, or an unannounced development such as an earnings miss, guidance cut, insider selling, or analyst downgrade that occurred within the 48-hour window but was not captured in the Yahoo Finance RSS feed provided.

AZTR

Azitra, Inc.Healthcare

$0.18−$0.03

-14.9%

AMEX · Mkt cap $2.0 M

Azitra reported Q1 2026 results on May 13, likely disappointing the market; the 14.9% drop suggests negative clinical, financial, or operational updates from the earnings announcement.

The stock fell sharply on the same day Azitra released Q1 2026 results and business updates. The headline indicates an earnings announcement but does not specify the actual results—cash burn rate, clinical trial progress, cash position, pipeline updates, or guidance changes are all unknown from the provided text. For a clinical-stage biopharmaceutical company trading at $0.18, typical sell-off triggers include: cash runway concerns, disappointing efficacy or safety data from trials, loss of a partnership, or weaker-than-expected cash position. The company's focus on precision dermatology is a niche market, and clinical biotech stocks are sensitive to binary clinical outcomes and balance sheet runway. Without access to the full earnings release, we cannot distinguish between a major clinical setback and routine quarterly burn that disappointed investors.

MBOT

Microbot Medical Inc.Healthcare

$1.85−$0.32

-14.7%

NASDAQ · Mkt cap $104 M

Microbot Medical fell 14.75% despite reporting a successful commercial transition and Q2 revenue already exceeding Q1, likely because Q1 revenue missed analyst estimates by 76.67%, signaling earlier-than-expected weakness that overshadowed positive forward guidance.

On May 13, MBOT reported Q1 2026 results showing a significant revenue miss of 76.67% versus estimates, though earnings beat by 37.50%. The same-day positive headline about the successful transition to full market release and accelerating Q2 revenue failed to offset the miss. In medical device stocks, especially pre-profitability or early-revenue companies, revenue shortfalls relative to consensus carry outsized weight because they suggest adoption is slower than expected or initial demand forecasts were too optimistic. The fact that Q2 revenue has already exceeded Q1 is encouraging forward guidance, but the market appears to have prioritized the hard miss on Q1 results and likely reassessed the company's ability to forecast accurately. The 14.75% drop ranks it 50th among daily losers, indicating broad sell-off rather than isolated concern.